Abbott (ABT) Announces Positive FDA Advisory Committee Review of Absorb

Go back to Abbott (ABT) Announces Positive FDA Advisory Committee Review of Absorb

Abbott's Absorbâ„¢, the First Fully Dissolving Heart Stent, Earns Positive Review by FDA Advisory Committee

March 15, 2016 4:57 PM EDT

WASHINGTON, March 15, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that an independent panel of experts convened by the U.S. Food and Drug Administration (FDA) voted 9 to 0, with one abstention, that the benefits of Abbott's Absorb fully bioresorbable drug eluting coronary stent outweigh the risks.

Absorb is a first-of-its-kind bioresorbable device for the treatment of coronary artery disease, which affects millions of adults nationwide and remains a leading cause of death despite decades of therapeutic advances. While most stents are made of metal, Abbott's Absorb stent is made of a naturally... More